Adverse Drug Reaction News Bulletins
ADR News Bulletin 2018 December (Volume 20 Number 3)
Audiences
Healthcare professional
Industry member
Product type
Therapeutic Products
1 December 2018
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Potential risk of new primary malignancy with Xgeva®
Early termination of ALLOZITHRO trial due to increased risk of relapse in haematopoietic stem cell transplantation patients treated with azithromycin for prophylaxis of bronchiolitis obliterans syndrome
Adverse event reports of liver injury suspected with the use of mahogany seeds
Highlights of drug-Adverse Event (AE) pairs of interest reviewed by HSA for the year 2018
Updates on adulterated products used for pain relief reported to HSA
Dear Healthcare Professional Letters
WHO-UMC-HSA Inter-Regional Pharmacovigilance Training Workshop 2018
Click on the link below to download the issue in pdf: